Clinical trial
Anlotinib in Combination With Sintilimab as Second-line Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC) : a Multicenter, Single-arm, Open-label Phase Ⅱ Clinical Trial
NCT04813406 is registered in ClinicalTrials.gov with Henan Provincial People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anlotinib in Combination With Sintilimab as Second-line Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC) : a Multicenter, Single-arm, Open-label Phase Ⅱ Clinical Trial
- Lead sponsor
- Henan Provincial People's Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- March 31, 2021
- Completion date
- January 31, 2022
- Enrollment
- 53 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.